ATOS News and Press, Atossa Therapeutics Inc. From 09/18/23

SEATTLE, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces that the Company will take par...

2023-09-08 12:29:30 ET More on Atossa Therapeutics Seeking Alpha’s Quant Rating on Atossa Therapeutics Historical earnings data for Atossa Therapeutics Financial information for Atossa Therapeutics Atossa Therapeutics: Betting Big On Transforming Old B...

2023-08-31 18:18:57 ET Summary Atossa Therapeutics is focusing on the development of a hormone therapy for hormone receptor-positive breast cancer, but the road to approval will be challenging. The company is testing the hormone therapy, endoxifen, in neoadjuvant therapy and risk ...

(NewsDirect) Atossa Therapeutics (NASDAQ:ATOS) President & CEO Dr. Steven Quay joins Thomas Warner from Proactive to speak about the latest developments in his and the clinical-stage biopharma company's fight against breast cancer. Dr. Quay gives an overview of ongoing clinical tr...

2023-08-14 12:37:08 ET Atossa Therapeutics, Inc. (ATOS) Q2 2023 Earnings Conference Call August 14, 2023 9:00 AM ET Company Participants Eric Van Zanten - Vice President of Investor and Public Relations Steven Quay - President and Chief Executive Officer Greg Wea...

2023-08-14 08:58:57 ET Atossa Therapeutics press release ( NASDAQ: ATOS ): Q2 GAAP EPS of -$0.08 misses by $0.02 . Total cash as of June 30, 2023, was $99.4M. For further details see: Atossa Therapeutics GAAP EPS of -$0.08 misses by $0.02

Achieved significant enrollment milestones in three ongoing Phase 2 clinical trials Broadened patent protection for proprietary (Z)-endoxifen Strengthened management team with appointment of Greg Weaver as Chief Financial Officer Ended second quarter 2023 with $99.4 millio...

2023-08-13 17:35:00 ET More on Atossa Therapeutics Atossa gains as Canada greenlights breast cancer trial Atossa jumps 17% after update on mid-stage trial for breast cancer drug Atossa announces new U.S. patent covering lead asset Atossa rebounds after enroll...

2023-08-13 08:02:00 ET More on Cisco, Deere, etc. Compare metrics for CSCO to DE, HD, SNDL, TGT, WMT Walmart: The Bottom Could Fall Out If Inflation Levels Continue To Fall Home Depot: Long-Term Winner, With Room To Run Target estimates lowered at Barclays ah...

2023-08-11 09:56:34 ET Major earnings expected before the bell on Monday include: Atossa Therapeutics ( ATOS ) JinkoSolar Holding ( JKS ) Niu Technologies ( NIU ) Sundial Growers ( SNDL ) 22nd Century Group ( XXII ) For further details see: ...